Roche entered a definitive merger agreement to acquire PathAI for $750M upfront plus up to $300M in milestones (total up to $1.05B). PathAI's AI-powered digital pathology platform will be integrated into Roche's Diagnostics division to scale companion diagnostic algorithms globally, building on the 2021/2024 partnership. Close expected H2 2026.